Cargando…

Predicting achievement of the treatment targets at 6 months from 3-month response levels in rheumatoid arthritis: data from real-life follow-up in the NOR-DMARD study

OBJECTIVE: When initiating a new therapy in patients with rheumatoid arthritis (RA), current treatment recommendations suggest escalating therapy in case of poor clinical improvement by 3 months or if the treatment target has not been reached by 6 months. We investigated which disease activity impro...

Descripción completa

Detalles Bibliográficos
Autores principales:	Norvang, Vibeke, Sexton, Joseph, Kristianslund, Eirik K, Olsen, Inge C, Uhlig, Till, Bakland, Gunnstein, Krøll, Frode, Rødevand, Erik, Wierød, Ada, Kvien, Tore K, Smolen, Josef S, Aletaha, Daniel, Haavardsholm, Espen A
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2018
Materias:	Rheumatoid Arthritis
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6242030/ https://www.ncbi.nlm.nih.gov/pubmed/30488000 http://dx.doi.org/10.1136/rmdopen-2018-000773

Ejemplares similares

Discontinuation rate of sulfasalazine, leflunomide and methotrexate due to adverse events in a real-life setting (NOR-DMARD)
por: Mielnik, Pawel, et al.
Publicado: (2023)

Comparative analyses of responsiveness between the Rheumatoid Arthritis Impact of Disease score, other patient-reported outcomes and disease activity measures: secondary analyses from the ARCTIC study
por: Holten, Karen, et al.
Publicado: (2018)

Inflammation and biologic therapy in patients with rheumatoid arthritis achieving versus not achieving ACR/EULAR Boolean remission in a treat-to-target study
por: Paulshus Sundlisæter, Nina, et al.
Publicado: (2022)

Effect of tapered versus stable treatment with tumour necrosis factor inhibitors on disease flares in patients with rheumatoid arthritis in remission: a randomised, open label, non-inferiority trial
por: Lillegraven, Siri, et al.
Publicado: (2023)

Fatigue in patients with early rheumatoid arthritis undergoing treat-to-target therapy: predictors and response to treatment
por: Holten, Karen, et al.
Publicado: (2022)

Comparing the disease course of patients with seronegative and seropositive rheumatoid arthritis fulfilling the 2010 ACR/EULAR classification criteria in a treat-to-target setting: 2-year data from the ARCTIC trial
por: Nordberg, Lena Bugge, et al.
Publicado: (2018)

Trajectories of fatigue in actively treated patients with established rheumatoid arthritis starting biologic DMARD therapy
por: Provan, Sella Aarrestad, et al.
Publicado: (2020)

Value of MRI and ultrasound for prediction of therapeutic response and erosive progression in patients with early rheumatoid arthritis managed by an aggressive treat-to-target strategy
por: Sundin, Ulf, et al.
Publicado: (2021)

Imputing missing data of function and disease activity in rheumatoid arthritis registers: what is the best technique?
por: Mongin, Denis, et al.
Publicado: (2019)

Comparative effectiveness of subcutaneous tocilizumab versus intravenous tocilizumab in a pan-European collaboration of registries
por: Lauper, Kim, et al.
Publicado: (2018)

Risk for infections with glucocorticoids and DMARDs in patients with rheumatoid arthritis
por: Riley, Thomas R, et al.
Publicado: (2021)

Serious infections in patients with rheumatoid arthritis and psoriatic arthritis treated with tumour necrosis factor inhibitors: data from register linkage of the NOR-DMARD study
por: Christensen, Ingrid Egeland, et al.
Publicado: (2022)

COVID-19 outcomes in patients with rheumatoid arthritis with biologic or targeted synthetic DMARDs
por: Tsai, Jih-Jin, et al.
Publicado: (2023)

Intermetatarsal bursitis is frequent in patients with established rheumatoid arthritis and is associated with anti-cyclic citrullinated peptide and rheumatoid factor
por: Hammer, Hilde Berner, et al.
Publicado: (2019)

Mining social media data to investigate patient perceptions regarding DMARD pharmacotherapy for rheumatoid arthritis
por: Sharma, Chanakya, et al.
Publicado: (2020)

Flare during tapering of biological DMARDs in patients with rheumatoid arthritis in routine care: characteristics and predictors
por: Terslev, L, et al.
Publicado: (2022)

Brief Report: Remission Rates With Tofacitinib Treatment in Rheumatoid Arthritis: A Comparison of Various Remission Criteria
por: Smolen, Josef S., et al.
Publicado: (2017)

Baricitinib further enhances disease-modifying effects by uncoupling the link between disease activity and joint structural progression in patients with rheumatoid arthritis
por: Lopez-Romero, Pedro, et al.
Publicado: (2022)

Tapering towards DMARD-free remission in established rheumatoid arthritis: 2-year results of the TARA trial
por: van Mulligen, Elise, et al.
Publicado: (2020)

Tapering glucocorticoids and risk of flare in rheumatoid arthritis on biological disease-modifying antirheumatic drugs (bDMARDs)
por: Adami, Giovanni, et al.
Publicado: (2023)

Response to baricitinib therapy in patients with rheumatoid arthritis with inadequate response to csDMARDs as a function of baseline characteristics
por: Kremer, Joel M, et al.
Publicado: (2018)

DMARD-free remission as novel treatment target in rheumatoid arthritis: A systematic literature review of achievability and sustainability
por: Verstappen, M, et al.
Publicado: (2020)

Effectiveness of SARS-CoV-2 vaccination in patients with rheumatoid arthritis (RA) on DMARDs: as determined by antibody and T cell responses
por: Saleem, Benazir, et al.
Publicado: (2022)

Clinical joint inactivity predicts structural stability in patients with established rheumatoid arthritis
por: Gärtner, M, et al.
Publicado: (2016)

Effect of disease duration and prior disease-modifying antirheumatic drug use on treatment outcomes in patients with rheumatoid arthritis
por: Aletaha, Daniel, et al.
Publicado: (2019)

Targeting type I interferon (IFN) signalling in patients with RA with a high type I IFN gene signature
por: Karonitsch, Thomas, et al.
Publicado: (2022)

Patient-reported outcomes from a phase III study of baricitinib in patients with conventional synthetic DMARD-refractory rheumatoid arthritis
por: Emery, Paul, et al.
Publicado: (2017)

‘Should we stop or continue conventional synthetic (including glucocorticoids) and targeted DMARDs before surgery in patients with inflammatory rheumatic diseases?’
por: Goodman, Susan M, et al.
Publicado: (2020)

Positive impact on 10-year outcome of the window of opportunity for conventional synthetic DMARDs in rheumatoid arthritis: results from the ESPOIR cohort
por: Kedra, Joanna, et al.
Publicado: (2022)

Patient and physician assessment in difficult-to-treat rheumatoid arthritis: patterns of subjective perception at early stages of b/tsDMARD treatment
por: Novella -Navarro, Marta, et al.
Publicado: (2023)

Synovial cellular and molecular signatures stratify clinical response to csDMARD therapy and predict radiographic progression in early rheumatoid arthritis patients
por: Humby, Frances, et al.
Publicado: (2019)

Effectiveness of electronic drug monitoring feedback to increase adherence in patients with RA initiating a biological DMARD: a randomised clinical trial
por: Hebing, Renske CF, et al.
Publicado: (2022)

Efficacy of non-conventional synthetic DMARDs for patients with rheumatoid arthritis-associated interstitial lung disease: a systematic review and meta-analysis
por: Yuan, Haoming, et al.
Publicado: (2023)

Tofacitinib in Combination With Methotrexate in Patients With Rheumatoid Arthritis: Clinical Efficacy, Radiographic, and Safety Outcomes From a Twenty‐Four–Month, Phase III Study
por: van der Heijde, Désirée, et al.
Publicado: (2019)

Anti-GM-CSF otilimab versus tofacitinib or placebo in patients with active rheumatoid arthritis and an inadequate response to conventional or biologic DMARDs: two phase 3 randomised trials (contRAst 1 and contRAst 2)
por: Fleischmann, Roy M, et al.
Publicado: (2023)

Effectiveness of TNF-inhibitors, abatacept, IL6-inhibitors and JAK-inhibitors in 31 846 patients with rheumatoid arthritis in 19 registers from the ‘JAK-pot’ collaboration
por: Lauper, Kim, et al.
Publicado: (2022)

Risk of herpes zoster (shingles) in patients with rheumatoid arthritis under biologic, targeted synthetic and conventional synthetic DMARD treatment: data from the German RABBIT register
por: Redeker, Imke, et al.
Publicado: (2022)

Short-term, intermediate-term and long-term risks of acute coronary syndrome in cohorts of patients with RA starting biologic DMARDs: results from four Nordic countries
por: Delcoigne, Benedicte, et al.
Publicado: (2022)

No impact of concomitant methotrexate use on serious adverse event and serious infection risk in patients with rheumatoid arthritis treated with bDMARDs: a systematic literature review and meta-analysis
por: Baradat, Claire, et al.
Publicado: (2017)

Real-world predictors of 12–month intravenous abatacept retention in patients with rheumatoid arthritis in the ACTION observational study
por: Alten, Rieke, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_r1kbpcdoevaopmiommsuqd7s90